Skip to main content
Avicenna Journal of Medical Biotechnology logoLink to Avicenna Journal of Medical Biotechnology
editorial
. 2019 Oct-Dec;11(4):269.

Microbiome and Schizophrenia

Shahin Akhondzadeh 1
PMCID: PMC6925402  PMID: 31908733

Schizophrenia is a debilitating psychiatric disorder that contributes to a large cascade of emotional, occupational, and cognitive impairments. Treatment involves combination of psychosocial rehabilitation and pharmacotherapy. In most cases, chronic antipsychotic therapy is required to treat symptoms, avoid relapse and attenuate episode recurrence 13. Despite the growing number of pharmacologic agents for the treatment of schizophrenia, many patients do not adequately benefit from or tolerate currently available antipsychotics 13. Existing typical and atypical antipsychotic medications are relatively equally effective in treating what are known as the positive symptoms of schizophrenia. What has been prominently lacking, however, is an agent that also treats the negative symptoms as well as substantial cognitive impairment 1–3. Despite growing numbers of antipsychotic drugs for the treatment of schizophrenia, the management of this disorder remains to be a major challenge. Therefore, there is a need to find new strategies to improve treatment plans for schizophrenia patients. New studies have found that people with schizophrenia have differences in their gut biomes compared to people without the mental disorder 4,5. The researchers found a smaller subset of bacteria that were clearly different between schizophrenia patients and those without the disorder. They report that when they introduced samples of the subset from the schizophrenia patients into the biomes of healthy mice, the mice displayed behavior changes 6,7. The researchers claim that their results show that people with schizophrenia have differences in their gut biomes and that those differences may be associated with schizophrenia symptoms. They suggest that certain bacteria in the biome may be associated with schizophrenia-related symptoms due to interactions with microbiota gut-brain amino acids, and possibly lipid metabolic pathways. In conclusion, researchers have started to find interesting links between the naturally occurring bacteria that live in our guts, and things we’ve traditionally attributed to the brain. Things like our mood, feelings, and even thoughts 8.

References

  • 1.Akhondzadeh S. The 5-HT hypothesis of schizophrenia. IDrugs 2001;4(3):295–300. [PubMed] [Google Scholar]
  • 2.Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 2010;116(2–3):101–106. [DOI] [PubMed] [Google Scholar]
  • 3.Ghajar A, Gholamian F, Tabatabei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, et al. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Hum Psychopharmacol 2018;33(4):e2662. [DOI] [PubMed] [Google Scholar]
  • 4.Severance EG, Yolken RH. From infection to the microbiome: An evolving role of microbes in schizophrenia. Curr Top Behav Neurosci 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv 2019;5(2):eaau8317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dinan TG, Cryan JF. Schizophrenia and the microbiome: Time to focus on the impact of antipsychotic treatment on the gut microbiota. World J Biol Psychiatry 2018;19(8):568–570. [DOI] [PubMed] [Google Scholar]
  • 7.Cuomo A, Maina G, Rosso G, Beccarini Crescenzi B, Bolognesi S, Di Muro A, et al. The microbiome: A new target for research and treatment of schizophrenia and its resistant presentations? A systematic literature search and review. Front Pharmacol 2018;9:1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dickerson F, Severance E, Yolken R. The microbiome, immunity, and schizophrenia and bipolar disorder. Brain Behav Immun 2017;62:46–52. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Avicenna Journal of Medical Biotechnology are provided here courtesy of Avicenna Research Institute

RESOURCES